In the Phase I/II clinical trial, pregnant women’s amniotic membrane („medical waste“) are used for mass culture of mesenchymal stem cells (MSC) and investigated for the treatment of Crohn’s disease and acute graft-versus-host disease (GVHD). In preclinical studies on amniotic MSC it was clarified that amniotic MSC have multipotency and immunosuppressive ability like bone marrow MSC. Additional features of amniotic MSC not found in bone marrow MSC are that they can be considered „medical waste“ available at low cost and at short term, rich in MSCs, which have high immunosuppressive ability.

AMED news release, December 12, 2017